NKGen Biotech, Inc.

NKGen Biotech, Inc. filed an 8-K with the SEC on October 5, 2023, under ticker GFOR, in connection with its business combination with Graf Acquisition Corp. IV. Graf Acquisition Corp. IV, sponsored by Graf Holdings LLC, completed its initial public offering in 2021 targeting the biotechnology and life sciences sector. NKGen Biotech is a clinical-stage biopharmaceutical company focused on natural killer cell-based immunotherapies, with programs directed at Alzheimer's disease and other indications. The filing marked the company's transition from blank-check SPAC vehicle to a publicly traded operating entity in the healthcare space. Sign up at SpacDesk for full filing history, deal timelines, and SPAC analytics on GFOR and hundreds of other transactions.